BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

Sanofi and AstraZeneca’s Beyfortus Receives HSA Approval to Prevent RSV in Infants

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety ...

August 20, 2025 | Regulatory

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Novo Nordisk’s Wegovy® Becomes First and Only GLP-1 Therapy Approved for MASH with Moderate to Advanced Fibrosis

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with modera...

August 18, 2025 | News

Superluminal Medicines and Eli Lilly Forge $1.3 Billion Collaboration on Undisclosed GPCR Targets in Cardiometabolic Disease and Obesity

Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as...

August 15, 2025 | News

Daewoong Korea’s Semaglutide Patch Achieves 80 Percent Bioavailability to Transform Obesity Care

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and...

August 14, 2025 | News

Remegen’s Telitacicept Hits Phase III Milestone in Primary Sjögren’s Syndrome

Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endp...

August 14, 2025 | News

Ascletis’ ASC47 Plus Tirzepatide Shows 87% Greater Weight Loss Than Tirzepatide Alone in Preclinical Obesity Study

The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to t...

August 13, 2025 | News

Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm

Local health authorities reported thousands of cases within weeks; by early August, figures converged around the several-thousand mark, with some reports t...

August 11, 2025 | Analysis

“Spatial Biology at Scale: 10x Genomics CEO Serge Saxonov on Redefining Precision Medicine with TISHUMAP”

The future of medicine is being shaped at the intersection of spatial biology and artificial intelligence—and 10x Genomics is l...

August 07, 2025 | Interaction

SOPHiA GENETICS and AstraZeneca Expand AI Collaboration to Advance Personalised Breast Cancer Care

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine,announced an expansion of its...

August 06, 2025 | News

iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...

August 06, 2025 | News

Fighting Dengue in a Changing Climate: Takeda’s Vision for Resilient Health Systems in Emerging Markets

Dengue is no longer a seasonal threat. It is a growing climate-driven crisis. With rising global temperatures, shifting rainfall patterns and rapid urbanis...

August 04, 2025 | Expert Insight

Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma

Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory C...

August 04, 2025 | News

Stay Connected